StreetInsider.com News Articles

Raymond James on Court Ruling: 'This should be viewed as a positive OSCR and other ACA exchange players as this puts to bed the $5 rule'

Mon, 15 Jun 2026 09:04:40 -0400

Raymond James analyst John Ransom reiterated an Outperform rating and $30.00 price target on Oscar Health Inc (NYSE: OSCR).

The analyst comments "On Friday, a federal judge struck down much of the 2025 marketplace integrity and affordability final rule that was finalized in June 2025 (HERE and HERE), but much of this rule was temporarily blocked or “stayed” backed in August 2025 (HERE), so much of this was never enacted. Items that changed - The most material change here was the shortened OEP window that was set to take effect in November 2026, which was originally not stayed. Additionally, a rule

Raymond James on Court Ruling: 'This should be viewed as a positive OSCR and other ACA exchange players as this puts to bed the $5 rule'

Mon, 15 Jun 2026 09:04:40 -0400

Raymond James analyst John Ransom reiterated an Outperform rating and $30.00 price target on Oscar Health Inc (NYSE: OSCR).

Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation'

Wed, 10 Jun 2026 07:34:14 -0400

(Updated - June 10, 2026 7:34 AM EDT)

Barclays analyst Andrew Mok upgraded Oscar Health Inc (NYSE: OSCR) from Equalweight to Overweight with a price target of $35.00 (from $30.00).

The analyst comments "Upgrade OSCR to OW: With single-line exposure to the Individual ACA market, we believe OSCR offers the most direct leverage to a potential multi-year multiple re-rating, alongside a margin recovery cycle as repricing actions take hold. Despite this setup, OSCR trades at 11.5x 2028 Bloomberg consensus EPS — toward the low end of the peer group and roughly half of ALHC’s multiple. Prior high-growth insurers such as CNC and

Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation'

Wed, 10 Jun 2026 07:34:14 -0400

(Updated - June 10, 2026 7:34 AM EDT)

Barclays analyst Andrew Mok upgraded Oscar Health Inc (NYSE: OSCR) from Equalweight to Overweight with a price target of $35.00 (from $30.00).

Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation'

Wed, 10 Jun 2026 07:34:14 -0400

(Updated - June 10, 2026 7:34 AM EDT)

Barclays analyst Andrew Mok upgraded Oscar Health Inc (NYSE: OSCR) from Equalweight to Overweight with a price target of $35.00 (from $30.00).

Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation'

Wed, 10 Jun 2026 07:34:14 -0400

(Updated - June 10, 2026 7:34 AM EDT)

Barclays analyst Andrew Mok upgraded Oscar Health Inc (NYSE: OSCR) from Equalweight to Overweight with a price target of $35.00 (from $30.00).

Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation'

Wed, 10 Jun 2026 07:34:14 -0400

(Updated - June 10, 2026 7:34 AM EDT)

Barclays analyst Andrew Mok upgraded Oscar Health Inc (NYSE: OSCR) from Equalweight to Overweight with a price target of $35.00 (from $30.00).

Form 8-K Oscar Health, Inc. For: Jun 04

Tue, 09 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260609/26623761.html

Form 8-K Oscar Health, Inc. For: Jun 04

Tue, 09 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260609/26623761.html

Form 4 Oscar Health, Inc. For: Jun 04 Filed by: Lang Laura W

Mon, 08 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260608/26617614.html

Form 4 Oscar Health, Inc. For: Jun 04 Filed by: Lang Laura W

Mon, 08 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260608/26617614.html

Form 4 Oscar Health, Inc. For: Jun 04 Filed by: WITTMAN VANESSA AMES